{"filing":{"accession_number":"0001628280-26-054341","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"vtgn-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026054341/vtgn-20260806.htm"},"events":[{"id":25909,"run_id":23524,"accession_number":"0001628280-26-054341","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Vistagen announced topline results from a Phase 2 repeat-dose clinical trial of fasedienol in social anxiety disorder, demonstrating favorable safety, efficacy signals across multiple endpoints, and nominally statistically significant results in the very severe social anxiety subpopulation (LSAS ≥95). For a clinical-stage biopharmaceutical company, clinical trial results on its most advanced product candidate are the primary driver of investor value and directly inform regulatory pathway discussions with the FDA.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26846,"accession_number":"0001628280-26-054341","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Vistagen issued a press release on August 6, 2026 announcing topline results of a Phase 2 repeat dose clinical study for fasedienol in social anxiety disorder. Although this is clinical trial data rather than financial earnings, it is a material disclosure of clinical progress on the company's most advanced product candidate. The study demonstrated favorable safety, efficacy signals across multiple endpoints, and nominally significant results in the very severe social anxiety subpopulation—findings that directly inform the company's regulatory pathway discussions with the FDA. For a clinical-stage biopharmaceutical company, clinical trial results are the primary driver of investor value and materiality, making this functionally equivalent to an earnings release in terms of investor impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:46:00.859295+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26847,"accession_number":"0001628280-26-054341","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced topline results from an exploratory Phase 2 clinical trial of fasedienol for social anxiety disorder. The study met its safety objective and showed numerical separation from placebo on primary endpoints, with nominally statistically significant findings in a prespecified subgroup of very severe patients (LSAS ≥95). While the study was not powered to demonstrate statistical significance overall, the results represent a material clinical development milestone that would inform FDA discussions regarding a potential registrational pathway. This is a clinical trial result disclosure that is operational/strategic in nature rather than a financial earnings release, and would materially affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:46:00.859295+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26846,"accession_number":"0001628280-26-054341","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Vistagen issued a press release on August 6, 2026 announcing topline results of a Phase 2 repeat dose clinical study for fasedienol in social anxiety disorder. Although this is clinical trial data rather than financial earnings, it is a material disclosure of clinical progress on the company's most advanced product candidate. The study demonstrated favorable safety, efficacy signals across multiple endpoints, and nominally significant results in the very severe social anxiety subpopulation—findings that directly inform the company's regulatory pathway discussions with the FDA. For a clinical-stage biopharmaceutical company, clinical trial results are the primary driver of investor value and materiality, making this functionally equivalent to an earnings release in terms of investor impact.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:46:00.859295+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-06"},{"id":26847,"accession_number":"0001628280-26-054341","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced topline results from an exploratory Phase 2 clinical trial of fasedienol for social anxiety disorder. The study met its safety objective and showed numerical separation from placebo on primary endpoints, with nominally statistically significant findings in a prespecified subgroup of very severe patients (LSAS ≥95). While the study was not powered to demonstrate statistical significance overall, the results represent a material clinical development milestone that would inform FDA discussions regarding a potential registrational pathway. This is a clinical trial result disclosure that is operational/strategic in nature rather than a financial earnings release, and would materially affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:46:00.859295+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-06"}]}